NLS Pharmaceutics And Kadimastem In Collaboration With ITolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For ITOL102 For Type 1 Diabetes
NLS Pharmaceutics And Kadimastem In Collaboration With ITolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For ITOL102 For Type 1 Diabetes
NLS醫藥公司與Kadimastem公司聯手ITolerance宣佈，針對ITOL102治療1型糖尿病的預先調查新藥會議請求已提交給FDA。
NLS Pharmaceutics And Kadimastem In Collaboration With ITolerance Announced That Request For Pre-Investigational New Drug Meeting Has Been Submitted To The FDA For ITOL102 For Type 1 Diabetes
NLS製藥公司與Kadimastem公司聯合ITolerance宣佈，已向FDA提交了關於ITOL102用於1型糖尿病的臨牀前新藥會議請求。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。